Patents Examined by Jeff Siew
  • Human PEN11B-related gene variant associated with lung cancers
    Patent number: 7108973
    Abstract: The invention relates to a novel human PEN11B-related gene variant, and to the use of the nucleic acid of the gene variant in diagnosing diseases, in particular, lung cancer, e.g. small cell lung cancer.
    Type: Grant
    Filed: March 20, 2002
    Date of Patent: September 19, 2006
    Inventor: Ken-Shwo Dai
  • Human ARL-related gene variants associated with cancers
    Patent number: 7087733
    Abstract: The invention relates to the nucleic acid sequences of two novel human ARL-related gene variants (ARLV1 and ARLV2) and the polypeptides encoded by ARLV1 and ARLV2. The invention also relates to the process for producing the polypeptides encoded by ARLV1 and ARLV2. The invention further relates to the use of the nucleic acid of ARLV1 and ARLV2 and the polypeptide encoded by ARLV1 and ARLV2 in diagnosing diseases associated with the deficiency of human ARLV gene, in particular large cell lung cancer or hepatocellular carcinoma.
    Type: Grant
    Filed: September 2, 2003
    Date of Patent: August 8, 2006
    Inventor: Ken-Shwo Dai
  • Use of protein biomolecular targets in the treatment and visualization of brain tumors
    Patent number: 7060275
    Abstract: The present invention relates to the use of proteins which are differentially expressed in primary brain tumor tissues, as compared to normal brain tissues, as biomolecular targets for brain tumor treatment therapies. Specifically, the present invention relates to the use of immunotherapeutic and immunoimaging agents which specifically bind to one or more of human proteins angiopoietin related protein 2 (ARP-2,) secreted protein acidic, rich in cysteine (SPARC,) c-met proto-oncogene (C-MET,) brevican (BEHAB,) CD-44 antigen (CD-44,) tetraspanin 3 (TSPN3,) pleiotrophin (PTN,) osteopontin (OPN,) vasoactive intestinal peptide receptor-2 (VIPR-2,) and receptor protein tyrosine phosphatase zeta (PTP?) for the treatment and visualization of brain tumors in patients. The present invention also provides compounds and pharmaceutically acceptable compositions for administration in the methods of the invention. The present invention also provides novel splice variants of protein PTP?, PTP? SM1 and PTP? SM2.
    Type: Grant
    Filed: August 28, 2003
    Date of Patent: June 13, 2006
    Assignee: AGY Therapeutics, Inc.
    Inventors: Sabine Mueller, Thorsten Melcher, Daniel Chin
  • GD3 peptide mimics
    Patent number: 6998237
    Abstract: The present invention provides peptide mimics for GD3 ganglioside. The peptide mimics were identified by panning phage display peptide libraries with an anti-GD3 monoclonal antibody. The peptide mimics inhibit the binding of an anti-GD3 antibody to GD3 positive cells and also elicit antibodies which can bind to GD3 positive cells. The identified peptide mimics can be used as immunogens for cancer therapy.
    Type: Grant
    Filed: July 11, 2003
    Date of Patent: February 14, 2006
    Assignee: Health Research, Inc.
    Inventors: Soldano Ferrone, Xinhui Wang, Jeff Chi-Feng Hsu, Chun-Yen Tsao, Wei Luo